KR102506460B1 - 알츠하이머병（ａｄ）의 치료 및 예방 - Google Patents

알츠하이머병（ａｄ）의 치료 및 예방 Download PDF

Info

Publication number
KR102506460B1
KR102506460B1 KR1020167033324A KR20167033324A KR102506460B1 KR 102506460 B1 KR102506460 B1 KR 102506460B1 KR 1020167033324 A KR1020167033324 A KR 1020167033324A KR 20167033324 A KR20167033324 A KR 20167033324A KR 102506460 B1 KR102506460 B1 KR 102506460B1
Authority
KR
South Korea
Prior art keywords
aluminum
aluminum salt
administered
patient
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167033324A
Other languages
English (en)
Korean (ko)
Other versions
KR20160145821A (ko
Inventor
마르쿠스 맨들러
아힘 슈네베르거
볼프강 자우어
아르네 본 보닌
프란크 마트너
발터 슈미트
Original Assignee
어드밴티지 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어드밴티지 테라퓨틱스, 인코포레이티드 filed Critical 어드밴티지 테라퓨틱스, 인코포레이티드
Publication of KR20160145821A publication Critical patent/KR20160145821A/ko
Application granted granted Critical
Publication of KR102506460B1 publication Critical patent/KR102506460B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
KR1020167033324A 2014-04-29 2015-04-29 알츠하이머병（ａｄ）의 치료 및 예방 Active KR102506460B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14166388 2014-04-29
EP14166355.9 2014-04-29
EP14166388.0 2014-04-29
EP14166355 2014-04-29
PCT/EP2015/059341 WO2015165968A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (2)

Publication Number Publication Date
KR20160145821A KR20160145821A (ko) 2016-12-20
KR102506460B1 true KR102506460B1 (ko) 2023-03-03

Family

ID=53039897

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167033324A Active KR102506460B1 (ko) 2014-04-29 2015-04-29 알츠하이머병（ａｄ）의 치료 및 예방

Country Status (12)

Country Link
US (3) US11065273B2 (https=)
EP (2) EP4209222A1 (https=)
JP (1) JP2017515812A (https=)
KR (1) KR102506460B1 (https=)
CN (1) CN106659736A (https=)
AU (1) AU2015254665A1 (https=)
CA (1) CA2946931A1 (https=)
DK (1) DK3137094T3 (https=)
FI (1) FI3137094T3 (https=)
PL (1) PL3137094T3 (https=)
PT (1) PT3137094T (https=)
WO (1) WO2015165968A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3137094T3 (pl) 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
EP3137097B1 (en) * 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)
EP3137093B1 (en) * 2014-04-29 2017-09-13 Affiris AG Treatment and prevention of alzheimer's disease (ad)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502802A (ja) * 1997-12-02 2002-01-29 ニューララブ リミテッド アミロイド形成疾患の予防および処置
WO2011120924A1 (en) * 2010-03-29 2011-10-06 Novartis Ag Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (en) 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
JP4662719B2 (ja) * 2002-04-19 2011-03-30 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント アルツハイマー病の処置のための免疫学的方法および組成物
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
WO2009105641A2 (en) 2008-02-20 2009-08-27 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
EP2145898A1 (en) * 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
EP3137097B1 (en) 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)
EP3137093B1 (en) 2014-04-29 2017-09-13 Affiris AG Treatment and prevention of alzheimer's disease (ad)
PL3137094T3 (pl) 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502802A (ja) * 1997-12-02 2002-01-29 ニューララブ リミテッド アミロイド形成疾患の予防および処置
WO2011120924A1 (en) * 2010-03-29 2011-10-06 Novartis Ag Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant

Also Published As

Publication number Publication date
DK3137094T3 (da) 2023-02-27
CA2946931A1 (en) 2015-11-05
CN106659736A (zh) 2017-05-10
FI3137094T3 (fi) 2023-03-20
KR20160145821A (ko) 2016-12-20
WO2015165968A1 (en) 2015-11-05
AU2015254665A1 (en) 2016-11-10
US20170049810A1 (en) 2017-02-23
EP3137094B1 (en) 2022-12-07
PT3137094T (pt) 2023-03-09
JP2017515812A (ja) 2017-06-15
US20220000908A1 (en) 2022-01-06
PL3137094T3 (pl) 2023-03-13
US11065273B2 (en) 2021-07-20
EP3137094A1 (en) 2017-03-08
US20240148782A1 (en) 2024-05-09
US11857568B2 (en) 2024-01-02
EP4209222A1 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
US20220062412A1 (en) Treatment of alzheimer's disease (ad) with an aluminum salt
KR102388363B1 (ko) 알츠하이머병（ａｄ）의 치료 및 예방

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000